文献速递糖尿病

MODY-单基因糖尿病的患者诊疗路径

Approach to the Patient with MODY-Monogenic Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本文系统阐述MODY-单基因糖尿病的诊断与治疗路径,强调结合临床特征、多代家族史及抗体检测识别患者,抗体阴性且具临床特征者应行基因检测;MODY临床风险计算器(>25%验后概率)及餐后尿C肽/肌酐比值(≥0.2 nmol/mmol)有助于鉴别;治疗及并发症监测取决于具体基因变异。

要点

  • 抗体阴性且具临床特征者应行MODY基因检测
  • MODY风险计算器验后概率>25%时触发基因检测
  • 餐后尿C肽/肌酐比值≥0.2 nmol/mmol可鉴别HNF1A/4A-MODY与1型糖尿病

核心结论

  • MODY-单基因糖尿病诊断不足,但通过临床特征、家族史及经济有效的实验室和基因检测可准确诊断。
  • 治疗及微血管和大血管并发症监测由所鉴定的特定基因变异决定。

研究设计与样本

  • 本文为针对患者的诊疗路径综述,基于临床经验与文献总结。

主要发现

  • 所有患者均应进行完整病史、体格检查、多代家族史及实验室评估(HbA1c、GADA、IA-2A、ZnT8抗体)。
  • 存在临床特征且3个或以上抗体阴性可能提示MODY-单基因糖尿病,应随后进行基因检测。
  • 在大多数情况下,尝试特定治疗前应进行分子基因检测。
  • MODY临床风险计算器在诊断后6个月内未接受胰岛素治疗的患者中验后概率>25%应触发基因检测。
  • 餐后(一天中最大餐后)2小时尿C肽/肌酐比值≥0.2 nmol/mmol可区分HNF1A-或4A-MODY与1型糖尿病。

关键数值与推荐

  • 3个或以上抗体(GADA、IA-2A、ZnT8)阴性结合临床特征提示MODY-单基因糖尿病。
  • MODY临床风险计算器验后概率>25%(适用于诊断后6个月内未用胰岛素治疗的患者)应触发基因检测。
  • 餐后2小时尿C肽/肌酐比值≥0.2 nmol/mmol用于区分HNF1A-或4A-MODY与1型糖尿病。

临床怎么用

  • 对疑似MODY患者应详细采集多代家族史并检测HbA1c、GADA、IA-2A、ZnT8抗体。
  • 抗体阴性且具临床特征者使用MODY风险计算器评估,验后概率>25%时行基因检测。
  • 基因检测明确变异前避免特定治疗,诊断后6个月内未用胰岛素者尤需评估。
  • 根据特定基因变异制定个体化治疗方案并监测微血管和大血管并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Maturity-onset diabetes of the young, or MODY-monogenic diabetes, is a not-so-rare collection of inherited disorders of non-autoimmune diabetes mellitus that remains insufficiently diagnosed despite increasing awareness. These cases are important to efficiently and accurately diagnose, given the clinical implications of syndromic features, cost-effective treatment regimen, and the potential impact on multiple family members. Proper recognition of the clinical manifestations, family history, and cost-effective lab and genetic testing provide the diagnosis. All patients must undergo a thorough history, physical examination, multigenerational family history, lab evaluation (glycated hemoglobin A1c [HbA1c], glutamic acid decarboxylase antibodies [GADA], islet antigen 2 antibodies [IA-2A], and zinc transporter 8 [ZnT8] antibodies). The presence of clinical features with 3 (or more) negative antibodies may be indicative of MODY-monogenic diabetes, and is followed by genetic testing. Molecular genetic testing should be performed before attempting specific treatments in most cases. Additional testing that is helpful in determining the risk of MODY-monogenic diabetes is the MODY clinical risk calculator (>25% post-test probability in patients not treated with insulin within 6 months of diagnosis should trigger genetic testing) and 2-hour postprandial (after largest meal of day) urinary C-peptide to creatinine ratio (with a ≥0.2 nmol/mmol to distinguish HNF1A- or 4A-MODY from type 1 diabetes). Treatment, as well as monitoring for microvascular and macrovascular complications, is determined by the specific variant that is identified. In addition to the diagnostic approach, this article will highlight recent therapeutic advancements when patients no longer respond to first-line therapy (historically sulfonylurea treatment in many variants). LEARNING OBJECTIVES: Upon completion of this educational activity, participants should be able to. TARGET AUDIENCE: This continuing medical education activity should be of substantial interest to endocrinologists and all health care professionals who care for people with diabetes mellitus.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Broome DT, Pantalone KM, Kashyap SR, et al. Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab. 2021. PMID: 33034350. doi:10.1210/clinem/dgaa710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。